[Skip to Navigation]
Sign In
Comment & Response
August 6, 2020

Assessing Expression of PD-L1 in Tumor-Associated Macrophages

Author Affiliations
  • 1Department of Thoracic Surgery, The First Affiliated Hospital of Xi’an Jiaotong University, Xi’an, Shaanxi, China
JAMA Oncol. 2020;6(10):1634. doi:10.1001/jamaoncol.2020.2698

To the Editor We read with interest the article by Jabbour et al1 regarding their phase 1 trial of pembrolizumab administered concurrently with chemoradiotherapy for locally advanced non–small cell lung cancer (NSCLC). This nonrandomized controlled trial highlights that combined treatment for stage III NSCLC is safe and tolerable, with promising progression-free survival; however, we have some questions.

Add or change institution